Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma
By J. Christensen, H. Zou, M. Arango, Qiuhua Li, Joseph H. Lee, S. McDonnell, S. Yamazaki, G. Alton, B. Mroczkowski, G. Los. Molecular Cancer Therapeutics, 2007
642 citations recorded by the source corpus.
Subfields: Oncology, Pathology and Forensic Medicine, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/1489cc1f3dc3719accfc686b68eeec509f7456aa
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
Citations in the corpus
- Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. (2009, background): “%) of 23 patients with EGFR mutations had a documented clinical response to an EGFR TKI.”